Director/PDMR Shareholding

RNS Number : 0316A

Allergy Therapeutics PLC

01 October 2009

 



Thursday 1 October 2009 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Directors' Holdings 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that, further to an announcement dated 25 September 2009, the 16,273,393 ordinary shares issued to Azure Ventures Limited, pursuant to a partial exercise of a warrant on 24 September 2009 have been admitted to trading on AIM. 

Azure Ventures Limited is now interested in 132,940,059 shares, representing 45.41 per cent. of the Company's total voting rights. 

Alejandro Weinstein, a non-executive director of the Company, is one of the ultimate beneficiaries under the Karjiang Pharma Trust which is the sole shareholder of Azure Ventures Limited. 

The Company's issued share capital consists of 292,771,944 ordinary shares. 

For further information

Allergy Therapeutics	[phone]
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

 

END

 

 

RDSGRBDGLUGGGCB